Neurocrine Biosciences, a prominent player in the biotechnology sector, recently faced a considerable setback in its quest to advance treatment options for major depressive disorder with the announcement that their experimental drug, NBI-’770, failed mid-stage clinical trials.
This news came on November 10, 2025, as the company disclosed that their trials involving 73 participants who had not responded well to existing antidepressants showed no significant improvement in depression symptoms when compared to a placebo.
While this could have been a major blow to the company’s pipeline, insights from their chief medical officer, Sanjay Keswani, suggest that some facets of the study data may still hold potential for further exploration.
In the context of an unpredictable market, investors reacted with a slight dip in stock prices, although overall expectations had been tempered due to skepticism surrounding NBI-’770’s prospects.
In this article, we will examine the clinical trial results of NBI-’770, the implications for Neurocrine Biosciences, and what the future may hold for both the company and the broader landscape of depression therapies.
Key Takeaways
- Neurocrine’s experimental depression drug, NBI-’770, failed to show efficacy in mid-stage trials, prompting concerns about its viability.
- Despite the setback with NBI-’770, analysts believe Neurocrine’s other drug, osavampator, still holds promise for future success.
- The company’s overall financial health remains strong with a significant increase in sales, showcasing resilience despite the recent trial failure.
Overview of NBI-’770 Clinical Trial Results
Overview of NBI-’770 Clinical Trial Results
On November 10, 2025, Neurocrine Biosciences delivered disappointing news regarding its experimental drug, NBI-’770, intended to treat major depressive disorder (MDD).
The drug, designed for patients who have not seen adequate results from existing antidepressants, underwent mid-stage clinical trials involving 73 participants.
Unfortunately, the trial results revealed that NBI-’770 did not yield substantial improvements compared to a placebo in alleviating symptoms of depression.
Despite this setback, Sanjay Keswani, Neurocrine’s chief medical officer, noted that certain data points might still hold potential for further exploration.
In response to the announcement, Neurocrine’s stock experienced a brief dip of approximately
1.5%, before showing signs of recovery in after-hours trading.
Analysts observed that the company’s valuation might not suffer severely from this trial’s failure, largely due to pre-existing low expectations regarding NBI-’770’s prospects.
While the potential for NBI-’770 appeared limited, the company’s other drug, osavampator, continues to garner attention as an effective add-on therapy and is advancing into later stages of trials.
Remarkably, despite the clinical trial disappointment, Neurocrine reported a 28% year-over-year increase in sales attributed to its leading products, Ingrezza and Crenessity.
However, concerns regarding possible commercial challenges for these drugs may have contributed to the initial decline in stock performance, highlighting the complex landscape of pharmaceutical advancements and market reactions.
Impact on Neurocrine Biosciences and Future Prospects
Following the disappointing results from the NBI-’770 clinical trial, Neurocrine Biosciences is strategically repositioning to maintain momentum in the competitive pharmaceutical landscape.
The company’s chief medical officer, Sanjay Keswani, remains optimistic about the therapeutic potential that may still exist within some trial data.
This approach indicates that Neurocrine is not merely accepting defeat but is instead looking to leverage insights gained to inform future research initiatives.
In parallel, the continued development of osavampator signals a commitment to innovative solutions for treating psychiatric conditions, particularly since it shows promise as an effective add-on therapy.
Neurocrine’s ability to report a significant 28% year-over-year increase in revenue, driven by strong sales of Ingrezza and Crenessity, underscores its resilience and diversified product strategy to offset setbacks.
Moreover, analysts are watching closely to gauge how the company navigates market challenges while seeking to capitalize on its existing portfolio, further emphasizing the importance of adaptability in the biopharmaceutical sector.
